drugset / Trial / NCT06425133
Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers
Phase 2
Recruiting
174 enrolled
Centre Hospitalier Universitaire de Besancon
Groupement Interrégional de Recherche Clinique et d'Innovation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The main objective is to evaluate the impact of a Regorafenib combined with metronomic chemotherapy (capecitabine and cyclophosphamide) and low-dose aspirin compared to standard Regorafenib treatment in patients with metastatic colorectal cancer by assessing progression-free survival.
Timeline
- Start
- 2024-07-19
- Primary completion
- 2027-09
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 75 mg | Oral |
| Subject | Capecitabine | Small molecule | 625 mg/m2 | Oral |
| Subject | Cyclophosphamide | Other / unclassified | 50 mg | Oral |
| Comparator | Regorafenib | Small molecule | 80 mg | — |
| Comparator | Regorafenib | Small molecule | 120 mg | — |
| Comparator | Regorafenib | Small molecule | 160 mg | — |